Evaluation of audiometric threshold shift criteria for ototoxicity monitoring

Journal of the American Academy of Audiology

Volumn 21, Issue 5, 2010, Pages 301-304

  Konrad Martin, Dawn ^a,b   James, Kenneth E ^a,d   Gordon, Jane S ^a   Reavis, Kelly M ^a   Phillips, David S ^a,d   Bratt, Gene W ^b,c   Fausti, Stephen A ^a,b  

^a NATIONAL CENTER FOR REHABILITATIVE AUDITORY RESEARCH   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c DEPARTMENT OF VETERANS AFFAIRS   (United States)

^d VANDERBILT UNIVERSITY   (United States)

Author keywords

Audiologic monitoring testing; Distortion product otoacoustic emissions; Hearing loss; High frequency audiometry; Ototoxicity monitoring; Tinnitus; Veteran

Indexed keywords

ANTIBIOTIC AGENT; CISPLATIN;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; AUDIOMETRY; CLINICAL EVALUATION; CONTROLLED STUDY; GOLD STANDARD; HEARING LOSS; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OTOTOXICITY; PATIENT MONITORING; PRIORITY JOURNAL; PROSPECTIVE STUDY; PURE TONE AUDIOMETRY; SIGNIFICANT THRESHOLD SHIFT AUDIOMETRY; SOUND INTENSITY; TASK PERFORMANCE; VETERAN;

ANTINEOPLASTIC AGENTS; AUDITORY THRESHOLD; CISPLATIN; DRUG MONITORING; HEARING LOSS; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; OTOACOUSTIC EMISSIONS, SPONTANEOUS; PROGNOSIS; PROSPECTIVE STUDIES; ROC CURVE;

EID: 77954260645     PISSN: 10500545     EISSN: None     Source Type: Journal    
DOI: 10.3766/jaaa.21.5.3     Document Type: Article

References (48)

1. American National Standards Institute (ANSI). (1989) American National Standard Specification for Audiometers (ANSI S3.6-1989). New York: American National Standards Institute.
2. American Speech-Language-Hearing Association (ASHA). (1994) Guidelines for the audiologic management of individuals receiving cochleotoxic drug therapy. ASHA 36:11-19.
3. Bertolini P, Lassalle M, Mercier G, et al. (2004) Platinum compound-related ototoxicity in children: long-term follow-up reveals continuous worsening of hearing loss. J Pediatr Hematol Oncol 26(10):649-655. (Pubitemid 39350398)
4. Blakley BW, Gupta AK, Myers SF, Schwan S. (1994) Risk factors for ototoxicity due to cisplatin. Arch Otolaryngol Head Neck Surg 120(5):541-546.
5. Bokemeyer C, Berger CC, Hartmann JT, et al. (1998) Analysis of risk factors for cisplatin-induced ototoxicity in patients with testicular cancer. Br J Cancer 77(8):1355-1362. (Pubitemid 28140629)
6. Brock P, Bellman S. (1991) Ototoxicity of cisplatinum. Br J Cancer 63:159-160.
7. Brummett RE. (1980) Drug-induced ototoxicity. Drugs 19(6): 412-428.
8. Carhart R, Jerger J. (1959) Preferred method for clinical determination of pure-tone thresholds. J Speech Hear Disord 24: 330-345.
9. Daniell WE, Stover BD, Takaro TK. (2003) Comparison of criteria for significant threshold shift in workplace hearing conservation programs. J Occup Environ Med 45(3):295-304.
10. Dobie RA. (1983) Reliability and validity of industrial audiometry: implications for hearing conservation program design. Laryngoscope 93(7):906-927.
11. Dobie RA. (2005) Audiometric threshold shift definitions: simulations and suggestions. Ear Hear 26:62-77.
12. Dreschler WA, van der Hulst RJ, Tange RA, Urbanus NA. (1989) Role of high-frequency audiometry in the early detection of ototoxicity. II. Clinical aspects. Audiology 28(4):211-220.
13. Ekborn A, Laurell G, Andersson A, Wallin I, Eksborg S, Ehrsson H. (2000) Cisplatin-induced hearing loss: influence of the mode of drug administration in the guinea pig. Hear Res 140:38-44. (Pubitemid 30079633)
14. Fausti SA, Frey RH, Erickson DA, Rappaport BZ, Cleary EJ, Brummett RE. (1979) A system for evaluating auditory function from 8000-20000 Hz. J Acoust Soc Am 66(6):1713-1718.
15. Fausti SA, Frey RH, Henry JA, Knutsen JL, Olson DJ. (1990) Reliability and validity of high-frequency (8-20 kHz) thresholds obtained on a computer-based audiometer as compared to a documented laboratory system. J Am Acad Audiol 1(3): 162-170.
16. th octave steps. J Am Acad Audiol 14(8): 444-450.
17. Fausti SA, Henry JA, Helt WJ, et al. (1999) An individualized, sensitive frequency range for early detection of ototoxicity. Ear Hear 20(6):497-505.
18. Fausti SA, Henry JA, Schaffer HI, Olson DJ, Frey RH, Bagby GC, Jr. (1993) High-frequency monitoring for early detection of cisplatin ototoxicity. Arch Otolaryngol Head Neck Surg 1196:661-666. (Pubitemid 23161975)
19. Fausti SA, Henry JA, Schaffer HI, Olson DJ, Frey RH, McDonald WJ. (1992) High-frequency audiometric monitoring for early detection of aminoglycoside ototoxicity. J Infect Dis 165(6):1026-1032.
20. Fausti SA, Larson VD, Noffsinger D, Wilson RH, Phillips DS, Fowler CG. (1994) High-frequency audiometric monitoring strategies for early detection of ototoxicity. Ear Hear 15(3): 232-239. (Pubitemid 24173826)
21. Fausti SA, Rappaport BZ, Schechter MA, Frey RH, Ward TT, Brummett RE. (1984) Detection of aminoglycoside ototoxicity by high-frequency auditory evaluation: selected case studies. Am J Otolaryngol 5(3):177-182.
22. Fausti SA, Henry JA, Helt WJ, Phillips DS, Frey RH, Noffsinger D, Larson VD, Fowler CG. (1999) An individualized, sensitive frequency range for early detection of ototoxicity. Ear Hear 20(6):497-505. (Pubitemid 30007547)
23. Frank T. (2001) High-frequency (8 to 16 kHz) reference thresholds and intrasubject threshold variability relative to ototoxicity criteria using a Sennheiser HDA 200 earphone. Ear Hear 22(2): 161-168.
24. Gordon JS, Phillips DS, Helt WJ, Konrad-Martin D, Fausti SA. (2005) Evaluation of insert earphones for high-frequency bedside ototoxicity monitoring. J Rehabil Res Dev 42(3):353-361. (Pubitemid 41105830)
25. Hanley JA, McNeil BJ. (1982) The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 143(1):29-36. (Pubitemid 12142173)
26. Hanley JA, McNeil BJ. (1983) A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 148(3):839-843.
27. Komune S, Asakuma S, Snow JB, Jr. (1981) Pathophysiology of the ototoxicity of cis-diamminedichloroplatinum. Otolaryngol Head Neck Surg 89(2):275-282.
28. Konishi T, Gupta BN, Prazma J. (1983) Ototoxicity of cisdichlorodiammine platinum (II) in guinea pigs. Am J Otolaryngol 4(1):18-26.
29. Kopelman J, Budnick AS, Sessions RB, Kramer MB, Wong GY. (1988) Ototoxicity of high-dose cisplatin by bolus administration in patients with advanced cancers and normal hearing. Laryngoscope 98(8, Pt. 1):858-864.
30. Matthews LJ, Lee FS, Mills JH, Dubno JR. (1997) Extended high-frequency thresholds in older adults. J Speech Lang Hear Res 40 (1):208-214.
31. Nagy JL, Adelstein DJ, Newman CW, Rybicki LA, Rice TW, Lavertu P. (1999) Cisplatin ototoxicity: the importance of baseline audiometry. Am J Clin Oncol 22(3):305-308.
32. Nakai Y, Konishi K, Chang KC, et al. (1982) Ototoxicity of the anti-cancer drug cisplatin. An experimental study. Acta Otolaryngol 93 (3-4):227-232.
33. National Institute for Occupational Safety and Health. (1998) Criteria for a Recommended Standard: Occupational Noise Exposure. NIOSH Publication No. 98-126. http://www.cdc.gov/ niosh/docs/98-126/ (accessed May 10, 2010).
34. Occupational Safety and Health Administration. (1983) Occupational noise exposure; hearing conservation amendment; final rule. 29CFR1910.95. Federal Register 48(46):9738-9785.
35. Pasic TR, Dobie RA. (1991) Cis-platinum ototoxicity in children. Laryngoscope 101(9):985-991.
36. Reavis KM, Phillips DS, Fausti SA, et al. (2008) Factors affecting sensitivity of distortion-product otoacoustic emissions to ototoxic hearing loss. Ear Hear 29(6):875-893.
37. Ress BD, Sridhar KS, Balkany TJ, Waxman GM, Stagner BB, Lonsbury-Martin BL. (1999) Effects of cis-platinum chemotherapy on otoacoustic emissions: the development of an objective screening protocol. Otolaryngol Head Neck Surg 121(6): 693-701.
38. Royster JD, Royster LH. (1986) Using audiometric data base analysis. J Occup Med 28(10):1055-1068. (Pubitemid 17194810)
39. Schaefer SD, Post JD, Close LG, Wright CG. (1985) Ototoxicity of low- and moderate-dose cisplatin. Cancer 56(8):1934-1939.
40. Schmuziger N, Probst R, Smurzynski J. (2004) Test-retest reliability of pure-tone thresholds from 0.5 to 16 kHz using Sennheiser HDA 200 and Etymotic Research ER-2 earphones. Ear Hear 25 (2):127-132.
41. Schweitzer VG. (1993) Cisplatin-induced ototoxicity: the effect of pigmentation and inhibitory agents. Laryngoscope 103(4, Pt. 2, Suppl. 59):1-52.
42. Schweitzer VG, Hawkins JE, Lilly DJ, et al. (1984) Ototoxic and nephrotoxic effects of combined treatment with cis-diamminedichloroplatinum and kanamycin in the guinea pig. Otolaryngol Head Neck Surg 92(1):38-49.
43. Simpson TH, Schwan SA, Rintelmann WF. (1992) Audiometric test criteria in the detection of cisplatin ototoxicity. J Am Acad Audiol 3(3):176-185.
44. Tange RA, Dreschler WA, van der Hulst RJ. (1985) The importance of high-tone audiometry in monitoring for ototoxicity. Arch Otorhinolaryngol 242(1):77-81.
45. van der Hulst RJ, Dreschler WA, Urbanus NA. (1988) High frequency audiometry in prospective clinical research of ototoxicity due to platinum derivatives. Ann Otol Rhinol Laryngol 97(2, Pt. 1):133-137.
46. van Zeijl LG, Conijn EA, Rodenburg M, Tange RA, Brocaar MP. (1984) Analysis of hearing loss due to cis-diamminedichloroplatinum- II. Arch Otorhinolaryngol 239(3):255-262.
47. Vaughan NE, Fausti SA, Chelius S, Phillips D, Helt W, Henry JA. (2002) An efficient test protocol for identification of a limited, sensitive frequency test range for early detection of ototoxicity. J Rehabil Res Dev 39(5):567-574.
48. Waters GS, Ahmad M, Katsarkas A, Stanimir G, McKay J. (1991) Ototoxicity due to cis-diamminedichloroplatinum in the treatment of ovarian cancer: influence of dosage and schedule of administration. Ear Hear 12(2):91-102.